Tetracycline
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-TETRACYCLINE |
|---|---|
| Type | Médicament |
| Alias | ActhromycinePylera (component, with bismuth + metronidazole)SumycineTetracycline hydrochlorideTétrosanТетрациклін |
| État | examinés 2026-05-18 |
| Maladies | DIS-GASTRIC |
| Sources | SRC-NCCN-BCELL-2025 |
Faits sur les drogues
| Catégorie | First-generation tetracycline antibiotic (broad-spectrum bacteriostatic) |
|---|---|
| Mécanisme | Tetracycline binds reversibly to the 30S ribosomal subunit at the A site, preventing aminoacyl-tRNA from associating with the ribosome and blocking the elongation step of bacterial protein synthesis. Bacteriostatic. Broad spectrum: Gram-positives, Gram-negatives, atypicals (Mycoplasma, Chlamydia, Rickettsia), spirochetes, Helicobacter pylori (including metronidazole- and clarithromycin-resistant strains in PBMT quadruple therapy). Distinct from doxycycline (semi-synthetic, longer half-life, better tissue penetration) — but cheaper and historically the canonical PBMT component. |
| Dose typique | H. pylori PBMT quadruple therapy (adult): 500 mg PO QID × 10-14 days, with PPI (omeprazole 20 mg BID) + bismuth subcitrate 120 mg QID + metronidazole 500 mg TID-QID. Take on empty stomach (1 hour before or 2 hours after meals) — food and dairy substantially reduce absorption. Separate from polyvalent cations (antacids, iron, calcium, dairy) by ≥2-3 hours. Renal adjustment: AVOID in renal impairment (CrCl <60) — tetracycline (unlike doxycycline) is renally excreted and accumulates; use doxycycline instead. Hepatic: caution in severe hepatic impairment; hepatotoxicity risk with high doses. Pediatric: contraindicated in children <8 years (permanent tooth discoloration, enamel hypoplasia, bone... |
| Ukraine enregistrée | Vrai |
| NSZU remboursé | Faux |
| Ukraine vérifiée pour la dernière fois | 2026-05-18 |
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Standard tetracycline component of PBMT (PPI + bismuth + metronidazole + tetracycline) — the preferred H. pylori regimen in regions with clarithromycin resistance >15% or after prior triple-therapy failure. Tetracycline (not doxycycline) is the evidence-based PBMT component per Maastricht VI / Florence consensus — doxycycline substitution has lower cure rates and is not equivalent. Pylera fixed-dose capsule (US/EU) bundles bismuth + metronidazole + tetracycline at lower per-component doses, taken QID × 10 days with PPI. Major patient adherence challenge: QID dosing × 10-14 days with meal-timing constraints and food/dairy/antacid spacing. Photosensitivity counseling required. In Ukraine, tetracycline aptechna availability has been spotty in some regions — verify supply before prescribing or use Pylera if available. Two-Co-Lead signoff queued for v0.2-A clinical review.
Utilisé par
Voies d'accès
AP-HP-ERADICATION-PHARMACY-OOP- H. pylori eradication (PPI + amox/clarithromycin / bismuth quadruple) — pharmacy out-of-p...
Protocole thérapeutique
REG-HP-BISMUTH-QUADRUPLE- Bismuth quadruple thérapie (PBMT) — 14 jours